Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald

Cantor Fitzgerald analyst Li Watsek raised the firm’s price target on Ascendis Pharma (ASND) to $254 from $203 and keeps an Overweight rating on the shares. The firm updated its patient flow model for Yorvipath and now sees largely in-line Q3 sales of $179M vs. $177M consensus, as the Street has caught up to the initial strong launch trajectory, the analyst tells investors in a research note.